Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including brain excitatory neurons; strongest in early spermatids | 0.75 |
| chemistry Open Targets | hard to drug: onasemnogene abeparvovec, risdiplam, nusinersen sodium +1 | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 3 Parkinson's papers of 1,477 | 0.82 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 11710
Sealed predictions
- SMN2 in dopamine neurons, braak+0.28 (p 0.470) → +0.10 (p 0.802)receipt 11718
Swarm cases
receipt 11718: SMN2 in dopamine neurons, braak
- power
- full sample +0.23 (p 0.365, n 18), 95% CI -0.27 to +0.63. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.21 (p 0.398, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.23 (p 0.365, n 18). could be the mix.
- skeptic
- leave-one-out range +0.13 to +0.31, sign flips 0; without severely affected donors +0.23 (p 0.365, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SMN2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts